Request Sample Inquiry
Autologous Cell Therapy Product Market

Autologous Cell Therapy Product Market

Autologous Cell Therapy Product Market - Global Industry Assessment & Forecast

Number Of Pages # Pages:

156

Base Year:

2021

Date

Feb - 2022

Format:

PDF XLS PPT

Report Code:

VMR-1298

Segments Covered
  • By Source Bone Marrow, Epidermis
  • By End User Hospitals, Ambulatory Centers, Research Centers
  • By Application Cancer, Neurodegenerative Diseases, Wound Healing, Orthopedic, CVD, Autoimmune Diseases
  • By Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Snapshot
Forecast YearsForecast Years: 2022 - 2028
Historical YearsHistorical Years: 2016 - 2021
Revenue 2021Revenue 2021: USD 10.54 Billion
Revenue 2028Revenue 2028: USD 34.8 Billion
Revenue CAGRRevenue CAGR (2022 - 2028): 17.1%
Fastest Growing Region Fastest Growing Region (2022 - 2028) Asia Pacific
Largest Region Largest Region (2021): North America
Customization Offered
  • Cross-segment Market Size and Analysis for Mentioned Segments
  • Additional Company Profiles (Upto 5 With No Cost)
  • Additional Countries (Apart From Mentioned Countries)
  • Country/Region-specific Report
  • Go To Market Strategy
  • Region Specific Market Dynamics
  • Region Level Market Share
  • Import Export Analysis
  • Production Analysis
  • Others Request Customization Speak To Analyst
Autologous Cell Therapy Product Market Share

Market Synopsis:

Global Autologous Cell Therapy Product market is valued at USD 10.54 Billion in 2021 and is projected to attain a value of USD 34.8 Billion by 2028 at a CAGR of 17.1% during the forecast period, 2022–2028. The increased frequency of chronic diseases such as autoimmune diseases, cancer, blood disorders, and others is one of the primary drivers driving the Autologous Cell Therapy Product industry. The demand for market growth is also being fueled by an increase in the number of people suffering from chronic ailments. According to the American Autoimmune Related Diseases Association (AARDA), around 50 million Americans have an autoimmune disease in 2018, and this number is likely to climb in the future. There are a few more variables that are vital in propelling the Autologous Cell Therapy Product market forward, one of which is ongoing medication development for new applications, which is predicted to further propel the Autologous Cell Therapy Product market forward.

Autologous Cell Therapy Product Market Size, 2021 To 2028 (USD Billion)

Most businesses have been working on the development of cell-based therapeutics for COVID-19 treatment, the impact of the COVID-19 pandemic on the Autologous Cell Therapy Product market is projected to be enormous. Because most pharmaceutical, biotechnology, and research organisations have been concentrating on the development of cell therapy-based treatment against COVID-19, the impact of COVID-19 is likely to have a beneficial impact on the studied market.

Rising Government Investments in Cell-Based Research

The demand for novel, better medicines for diseases like cancer and cardiovascular disease has led in an increase in general research effort, as well as financing for cell-based research. The Stem Cell Therapies Mission, a 10-year roadmap for stem cell research in Australia, was released by the Australian government in November 2019. Under the Medical Research Future Fund (MRFF), the project would grant USD 102 million (AU$150 million) to encourage stem cell research in order to develop novel medicines. The National Institutes of Health (NIH) has greatly boosted funding for the development of cell treatments in the United States over the years. The good financing situation is boosting demand for Autologous Cell Therapy Product research equipment, media, reagents, and accessories.

Dearth of Skilled Professionals

Despite technological advancements and product development over the last decade, the market has been hampered by a shortage of skilled workers who can operate sophisticated instruments like flow cytometers and multi-mode readers. Flow cytometers and spectrophotometers, which are technologically modern and very complicated, produce a wide range of data outputs that require skill to analyse and review. There remains, nevertheless, a global demand-supply gap for trained people.

Market Segmentation:

Global Autologous Cell Therapy Product market is segmented on the basis of Source into Bone Morrow & Epidermis. By End-User into Hospitals, Ambulatory Centers and Research Centers. By Application into Cancer, Neurodegenerative Diseases, Wound Healing, Orthopedic, CVD and Autoimmune Diseases. Based on region, the Autologous Cell Therapy Product market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Below tree is interactive. You can click the nodes to get more information.

North America to Continue Dominating the Autologous Cell Therapy Product Market

North America dominated the Autologous Cell Therapy Product market. The region has experienced great economic growth, has access to cutting-edge technology, and has seen significant corporate and public sector investment. Other factors driving the market in the region include the availability of cutting-edge research infrastructure, the simplicity with which clinical trials may be approved, and a growth in R&D initiatives aimed at developing therapeutic options for chronic diseases. The United States is a big contributor to the country's key market vendors and research firms. Several pipeline developments in the region are boosting market demand. Celgene and Evotec SE increased their partnership in June 2019 to include a novel iPSC that will now be used to recover disease-modifying medicines for patients with neurological illnesses.

Key Players:

Key participants operating in the Autologous Cell Therapy Product market are: Vericel Corporation (US), Pharmicell Co. Inc(South Korea), Holostem Terapie Avanzate S.R.L (Italy), Lineage Cell Therapeutics Inc. (US), Opexa Therapeutics (US)

The Autologous Cell Therapy Product market is segmented as follows:

Parameter Details
Segments Covered
  • Source (Bone Marrow, Epidermis)
  • End User (Hospitals, Ambulatory Centers, Research Centers)
  • Application (Cancer, Neurodegenerative Diseases, Wound Healing, Orthopedic, CVD, Autoimmune Diseases)
  • Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa)
Regions & Countries Covered
  • North America - (U.S., Canada, Mexico)
  • Europe - (U.K., France, Germany, Italy, Spain, Rest Of Europe)
  • Asia Pacific - (China, Japan, India, South Korea, South East Asia, Rest Of Asia Pacific)
  • Latin America - (Brazil, Argentina, Rest Of Latin America)
  • Middle East & Africa - (GCC Countries, South Africa, Rest Of Middle East & Africa)
Companies Covered
  • Vericel Corporation (US)
  • Pharmicell Co. Inc(South Korea)
  • Holostem Terapie Avanzate S.R.L (Italy)
  • Lineage Cell Therapeutics Inc. (US)
  • Opexa Therapeutics (US)
Report Coverage Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, technology landscape, patent analysis, market attractiveness analysis by segments and North America, company market share analysis, and COVID-19 impact analysis

The Autologous Cell Therapy Product market scope can be tabulated as below:

Autologous Cell Therapy Product Market Anticipated to Reach Valuation of USD 34.8 Billion by 2028
In terms of revenue, the Global Autologous Cell Therapy Product Market is expected to reach USD 34.8 Billion by 2028, growing at a Compound Annual Growth Rate (CAGR) of 17.1% from 2022 to 2028. The rising incidence of chronic conditions such as autoimmune diseases, blood disorders, cancer, and othe...
FAQ
Frequently Asked Question
  • The global Autologous Cell Therapy Product valued at USD 10.54 Billion in 2020 and is expected to reach USD 34.8 Billion in 2028 growing at a CAGR of 17.1%.

  • The prominent players in the market are Vericel Corporation (US), Pharmicell Co. Inc(South Korea), Holostem Terapie Avanzate S.R.L (Italy), Lineage Cell Therapeutics Inc. (US), Opexa Therapeutics (US).

  • The market is project to grow at a CAGR of 17.1% between 2021 and 2028.

  • The driving factors of the Autologous Cell Therapy Product include

    • Rising Government Investments in Cell-Based Research

  • North America was the leading regional segment of the Autologous Cell Therapy Product in 2020.